Lupin receives European Commission approval for biosimilar Ranibizumab

Axol Bioscience acquires ophthalmology business from Newcells Biotech

Acquisition expands Axol’s portfolio of iPSC-derived retinal organoid and retinal pigment epithelium (RPE) models

Zydus introduces ANYRA (Aflibercept 2 mg) for advanced retinal disease treatment

ANYRA is India’s first indigenously developed Aflibercept 2 mg biosimilar

Eyestem moves closer to blindness breakthrough with phase 2 trial green light

The early-stage trial demonstrated an excellent safety profile alongside clinically meaningful improvements in visual acuity

EU clears Eylea 8 mg for retinal vein occlusion, expanding use of long-acting eye therapy

Treatment typically requires frequent injections directly into the eye—an ongoing burden for patients and health systems alike

Complement Therapeutics’ gene therapy gains FDA fast-track for vision loss treatment

CTx001 targets Geographic Atrophy (GA) secondary to Age-related Macular Degeneration

Ollin Biosciences’ bispecific antibody outperforms Faricimab in head-to-head Phase 1b trial

DME is among the most challenging retinal diseases to treat and has long served as a proving ground for therapies that ultimately become first-line standard of care in retinal diseases

Lupin receives positive CHMP opinion for biosimilar Ranibizumab

Ranibizumab is a recombinant humanized IgG1 monoclonal antibody fragment that binds to and inhibits vascular endothelial growth factor A

Sanofi flags delay in FDA review of Tolebrutinib for progressive multiple sclerosis

EMA backs Eylea 8 mg for retinal vein occlusion

The positive CHMP opinion is supported by results from the Phase III QUASAR trial